Cullen Frost Bankers Inc. boosted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 12.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 358,482 shares of the pharmaceutical company's stock after purchasing an additional 38,779 shares during the quarter. Cullen Frost Bankers Inc.'s holdings in GSK were worth $13,888,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Olde Wealth Management LLC bought a new stake in shares of GSK in the 1st quarter worth approximately $36,000. Lee Danner & Bass Inc. bought a new position in shares of GSK during the fourth quarter valued at $39,000. First Pacific Financial bought a new position in shares of GSK during the first quarter valued at $45,000. CX Institutional bought a new position in shares of GSK during the first quarter valued at $46,000. Finally, Garde Capital Inc. acquired a new stake in GSK during the 1st quarter valued at $51,000. Institutional investors own 15.74% of the company's stock.
GSK Trading Down 0.5%
Shares of GSK stock traded down $0.18 during trading on Friday, reaching $36.29. 2,944,346 shares of the company were exchanged, compared to its average volume of 5,068,514. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The business has a 50-day moving average price of $38.99 and a 200-day moving average price of $37.36. The firm has a market capitalization of $74.29 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 1.55 and a beta of 0.50.
GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. During the same period in the previous year, the firm earned $0.43 earnings per share. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. Sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.
GSK Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were paid a dividend of $0.4216 per share. The ex-dividend date was Friday, May 16th. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.65%. GSK's payout ratio is 88.14%.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. BNP Paribas assumed coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target for the company. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $37.38.
View Our Latest Stock Report on GSK
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More

Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.